Equivalent cross-relaxation rate imaging and diffusion weighted imaging for early prediction of response to bevacizumab-containing treatment in colorectal liver metastases—preliminary study

Stremitzer, 2015, Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases, Eur J Surg Oncol, 41, 868, 10.1016/j.ejso.2015.03.223 Wicherts, 2011, Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases, Br J Surg, 98, 399, 10.1002/bjs.7368 Jiang, 2016, Ex-vivo imaging and plaque type classification of intracranial atherosclerotic plaque using high resolution MRI, Atherosclerosis, 249, 10, 10.1016/j.atherosclerosis.2016.03.033 Ratai, 2013, Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677, Neuro Oncol, 15, 936, 10.1093/neuonc/not044 Moffat, 2006, The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome, Neoplasia, 8, 259, 10.1593/neo.05844 Okuda, 2014, Equivalent cross-relaxation rate imaging positively correlates with pathological grade and cell density of adipocytic tumors, Magn Reson Imaging, 32, 206, 10.1016/j.mri.2013.12.004 Hamada, 2014, Correlation between equivalent cross-relaxation rate and cellular density in soft tissue tumors, Skeletal Radiol, 43, 141, 10.1007/s00256-013-1754-9 Nishiofuku, 2011, Cellular imaging using equivalent cross-relaxation rate technique in rabbit VX-2 tumor model, Cancer Inform, 10, 227, 10.4137/CIN.S7833 Nishiofuku, 2010, Cellular density evaluation for malignant lymphoma using equivalent cross-relaxation rate imaging-initial experience, Korean J Radiol, 11, 327, 10.3348/kjr.2010.11.3.327 Mastsushima, 2008, Equivalent cross-relaxation rate imaging of axillary lymph nodes in breast cancer, J Magn Reson Imaging, 27, 1278, 10.1002/jmri.21355 Hochster, 2008, Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study, J Clin Oncol, 20, 3523, 10.1200/JCO.2007.15.4138 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 D'Angelica, 2007, Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case–control study, Ann Surg Oncol, 14, 759, 10.1245/s10434-006-9074-0 Reddy, 2008, Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases, J Am Coll Surg, 206, 96, 10.1016/j.jamcollsurg.2007.06.290 Kesmodel, 2008, Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases, J Clin Oncol, 26, 5254, 10.1200/JCO.2008.17.7857 Vossen, 2009, Diffusion-weighted and Gd-EOB-DTPA-contrast-enhanced magnetic resonance imaging for characterization of tumor necrosis in an animal model, J Comput Assist Tomogr, 33, 626, 10.1097/RCT.0b013e3181953df3 Deng, 2008, Diffusion-weighted PROPELLER MRI for quantitative assessment of liver tumor necrotic fraction and viable tumor volume in VX2 rabbits, J Magn Reson Imaging, 27, 1069, 10.1002/jmri.21327 Song, 2008, Changes in 18F-FDG uptake within minutes after chemotherapy in a rabbit VX2 tumor model, J Nucl Med, 49, 303, 10.2967/jnumed.107.044206